Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).

被引：0
|
作者：
Dasari, Arvind
Li, Daneng
Sung, Max W.
Tucci, Christopher
Kauh, John S.
Kania, Marek K.
Paulson, Andrew Scott
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA USA
[3] Beckman Res Inst, Duarte, CA USA
[4] Tisch Canc Inst Mt Sinai, New York, NY USA
[5] Hutchison MediPharma, Florham Pk, NJ USA
[6] Eli Lilly & Co, Bridgewater, NJ USA
[7] Hutchison MediPharma Int Inc, Florham Pk, NJ USA
[8] Texas Oncol US Oncol Network, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4610
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs): A United States Experience
    Katona, Bryson
    Riff, Brian
    Soulen, Michael
    Pryma, Daniel
    Bennett, Bonita
    Wild, Damian
    Nicolas, Guillaume
    Teitelbaum, Ursina
    Metz, David
    PANCREAS, 2017, 46 (03) : 439 - 439
  • [22] EFFICACY AND SAFETY OF SOMATULINE AUTOGEL IN COMBINATION WITH MOLECULAR TARGETED THERAPIES (MTT) IN NEUROENDOCRINE TUMORS (NETS)
    Capdevila, J.
    Sevilla, I.
    Alonso, V.
    Anton-Aparicio, L.
    Jimenez Fonseca, P.
    Grande, E.
    Reina, J. J.
    Manzano, J. L.
    Alonso-Jara, J.
    Garcia Alfonso, P.
    ANNALS OF ONCOLOGY, 2012, 23 : 380 - 380
  • [23] Efficacy and safety profile of antivascular endothelial growth factor receptor tyrosine kinase inhibitors (avRTKIs) in patients (Pts) with neuroendocrine tumors(NETs): A systematic review and meta-analysis (SRMA).
    Das, Satya
    Phillips, Sharon E.
    Lee, Cody L.
    Laferriere, Heather E.
    Agarwal, Rajiv
    Ramirez, Robert A.
    Berlin, Jordan
    Dasari, Arvind
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16216 - E16216
  • [24] Clinical and pathological characteristics of patients with gastrointestinal neuroendocrine tumors in the United States
    El-Habashy, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S162 - S162
  • [25] A prospective, open-label study evaluating the efficacy and safety of Surufatinib (S) in combination with CAPTEM as conversion therapy in patients with unresectable pancreatic neuroendocrine tumors (pNET)
    Wang, Z.
    Cao, D.
    Ke, N.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 254 - 254
  • [26] Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors
    Ge, Wenhao
    Zhou, Dongkai
    Zhu, Lijun
    Song, Wei
    Wang, Weilin
    JOURNAL OF CANCER, 2018, 9 (24): : 4783 - 4790
  • [27] Burden of medication in patients with lung neuroendocrine tumors (NETs) in a US real-world setting
    Starr, J.
    Houchard, A.
    Pommie, C.
    Ribeiro-Oliveira, Jr A.
    Chan, J. A.
    Vandamme, T.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 129 - 129
  • [28] The Total Lifetime Cost of Treating Patients (Pts) with CLL in the United States (US)
    Awan, Farrukh T.
    Vidisheva, Aleksandra
    Saeedian, Matia
    Kurt, Murat
    Tiwana, Simran K.
    Priyadarshini, Masoom
    BLOOD, 2023, 142
  • [29] ELECT: A phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs)
    Vinik, Aaron
    Wolin, Edward M.
    Audry, Helene
    Gomez-Panzani, Edda L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [30] SAFETY, TECHNICAL EFFICACY AND LONG-TERM CLINICAL OUTCOMES OF ENDOSCOPIC THERAPY FOR FOREGUT NEUROENDOCRINE TUMORS (NETS)
    Yewale, Rohan
    Pagadapelli, Arun Arora
    Ajay, B. R.
    Korrapati, Sravan
    Ansari, Jaseem
    Borkar, Mangesh
    Bapaye, Amol
    GASTROINTESTINAL ENDOSCOPY, 2024, 99 (06) : AB1112 - AB1112
12345